# Clinical Study to Compare the Pharmacokinetic Characteristics and Safety Between CKD-380 10mg and D308 10mg

> **NCT03601910** · PHASE1 · UNKNOWN · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 34 (actual)

## Conditions studied

- Type II Diabetes Mellitus

## Interventions

- **DRUG:** D308 10mg Tab.
- **DRUG:** CKD-380 10mg Tab.

## Key facts

- **NCT ID:** NCT03601910
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07-16
- **Primary completion:** 2018-09-21
- **Final completion:** 2018-11-09
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2018-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03601910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03601910, "Clinical Study to Compare the Pharmacokinetic Characteristics and Safety Between CKD-380 10mg and D308 10mg". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03601910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*